Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BON NASDAQ:OBSV NASDAQ:TCON NASDAQ:VINC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBONBon Natural Life$1.88-3.1%$1.78$1.14▼$73.75$320K-0.351.74 million shs143,483 shsOBSVObsEva$0.00$0.08▼$2.14$394K0.688.94 million shs9,906 shsTCONTRACON Pharmaceuticals$0.03$0.04$0.00▼$14.75$110K1.37120,908 shs23,886 shsVINCVincerx Pharma$0.03-4.5%$0.04$0.03▼$10.37$167K1.78464,344 shs1,748 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBONBon Natural Life-3.00%-11.82%-4.43%+37.59%+193,999,900.00%OBSVObsEva0.00%+910.00%+910.00%+910.00%+152.50%TCONTRACON Pharmaceuticals0.00%0.00%0.00%0.00%-48.89%VINCVincerx Pharma+4.69%-22.09%-28.57%-43.03%-99.56%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBONBon Natural Life$1.88-3.1%$1.78$1.14▼$73.75$320K-0.351.74 million shs143,483 shsOBSVObsEva$0.00$0.08▼$2.14$394K0.688.94 million shs9,906 shsTCONTRACON Pharmaceuticals$0.03$0.04$0.00▼$14.75$110K1.37120,908 shs23,886 shsVINCVincerx Pharma$0.03-4.5%$0.04$0.03▼$10.37$167K1.78464,344 shs1,748 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBONBon Natural Life-3.00%-11.82%-4.43%+37.59%+193,999,900.00%OBSVObsEva0.00%+910.00%+910.00%+910.00%+152.50%TCONTRACON Pharmaceuticals0.00%0.00%0.00%0.00%-48.89%VINCVincerx Pharma+4.69%-22.09%-28.57%-43.03%-99.56%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBONBon Natural Life 1.00SellN/AN/AOBSVObsEva 0.00N/AN/AN/ATCONTRACON Pharmaceuticals 0.00N/AN/AN/AVINCVincerx Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TCON, OBSV, BON, and VINC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025BONBon Natural LifeWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025BONBon Natural LifeWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 10/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBONBon Natural Life$23.84M0.01$9.89 per share0.19$279.24 per share0.01OBSVObsEvaN/AN/AN/AN/A$0.41 per shareN/ATCONTRACON Pharmaceuticals$12.05M0.01$1.61 per share0.02($0.37) per share-0.09VINCVincerx PharmaN/AN/AN/AN/A$10.50 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBONBon Natural Life$400KN/A0.00∞N/AN/AN/AN/AN/AOBSVObsEva-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/ATCONTRACON Pharmaceuticals-$3.59M$3.730.01∞N/AN/A-237.65%57.29%N/AVINCVincerx Pharma-$40.16M-$20.60N/AN/AN/AN/A-248.33%-132.73%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBONBon Natural LifeN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/ATCONTRACON PharmaceuticalsN/AN/AN/AN/AN/AVINCVincerx PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBONBon Natural Life0.012.442.29OBSVObsEvaN/A0.610.61TCONTRACON PharmaceuticalsN/A0.660.66VINCVincerx PharmaN/A2.172.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBONBon Natural Life0.57%OBSVObsEva17.52%TCONTRACON Pharmaceuticals11.61%VINCVincerx Pharma44.02%Insider OwnershipCompanyInsider OwnershipBONBon Natural Life26.48%OBSVObsEva14.40%TCONTRACON Pharmaceuticals5.27%VINCVincerx Pharma15.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBONBon Natural Life100170,000123,000N/AOBSVObsEva5077.97 million66.74 millionNot OptionableTCONTRACON Pharmaceuticals203.41 million3.23 millionNo DataVINCVincerx Pharma605.23 million1.89 millionNot OptionableTCON, OBSV, BON, and VINC HeadlinesRecent News About These CompaniesVincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders ...July 16, 2025 | gurufocus.comVincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders to Vote FOR Approval of Dissolution ProposalJuly 16, 2025 | globenewswire.comVincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders | The ... - The Manila TimesJuly 9, 2025 | manilatimes.netMVincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders - MorningstarJuly 9, 2025 | morningstar.comMVincerx Pharma, Inc. Common Stock (VINC) - Yahoo FinanceJuly 8, 2025 | finance.yahoo.comVincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to StockholdersJuly 7, 2025 | globenewswire.comVincerx Pharma, Inc. (VINC) - Yahoo FinanceJuly 2, 2025 | ca.finance.yahoo.comVincerx Pharma, Inc. Announces Adjournment of Special Meeting - Will Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution ProposalJune 18, 2025 | globenewswire.comVincerx Pharma announces plan to delist from NasdaqApril 18, 2025 | markets.businessinsider.comVincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SECApril 17, 2025 | finance.yahoo.comVincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SECApril 17, 2025 | globenewswire.comVincerx's final merger attempt collapses, leaving ADC biotech to wind downApril 9, 2025 | fiercebiotech.comFVincerx terminates letter of intent with Global Digital, initiates wind downApril 9, 2025 | markets.businessinsider.comFinancially struggling drugmaker's potential rescue falls apart. It now will wind downApril 9, 2025 | bizjournals.comVincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down ActivitiesApril 8, 2025 | globenewswire.comVincerx Pharma announces non-binding LOI for Qumulus AI combinationMarch 18, 2025 | markets.businessinsider.comVincerx Pharma, Inc.: Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAIMarch 18, 2025 | finanznachrichten.deVincerx, left in limbo by collapsed deal, moves to merge with AI company to escape cash crisisMarch 18, 2025 | fiercebiotech.comFVincerx Pharma Shares Soar on Proposed Merger with Global Digital HoldingsMarch 18, 2025 | marketwatch.comVincerx Pharma, Inc. Announces Non-Binding Letter of Intent for Business Combination with QumulusAIMarch 18, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025Rocket Lab's Electron: The Quiet Workhorse Powering MomentumBy Ryan Hasson | October 2, 2025Quanta Services: The Backbone of the AI Data Center PushBy Jordan Chussler | October 23, 2025TCON, OBSV, BON, and VINC Company DescriptionsBon Natural Life NASDAQ:BON$1.88 -0.06 (-3.09%) Closing price 04:00 PM EasternExtended Trading$1.88 0.00 (0.00%) As of 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bon Natural Life Limited, together with its subsidiaries, engages in the research and development, manufacture, and sale of functional active ingredients extracted from natural herb plants in the People's Republic of China and internationally. The company provides personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers; natural health supplements comprising powder drinks and bioactive food ingredient products primarily used as food additives; and nutritional supplements. Its products are principally used by manufacturer customers in the functional food, personal care, cosmetic, and pharmaceutical industries. The company was founded in 2006 and is headquartered in Grand Cayman, the Cayman Islands.ObsEva NASDAQ:OBSVObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.TRACON Pharmaceuticals NASDAQ:TCONTRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.Vincerx Pharma NASDAQ:VINC$0.03 0.00 (-4.48%) As of 03:43 PM EasternVincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 GM Posts Largest Gain Since the Pandemic: Shares Still Look Cheap 3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
